Voriconazole as an alternative oral treatment in fluconazole-resistant urinary candidiasis.

Autor: Boglione-Kerrien C; CHU Rennes, Laboratory of Biological Pharmacology, F-35000 Rennes, France. Electronic address: christelle.boglione-kerrien@chu-rennes.fr., Le Bot A; CHU Rennes, Infectious Diseases and Intensive Care Unit, F-35000 Rennes, France., Luque Paz D; CHU Rennes, Infectious Diseases and Intensive Care Unit, F-35000 Rennes, France., Verdier MC; CHU Rennes, Laboratory of Biological Pharmacology, F-35000 Rennes, France; Univ Rennes, CHU de Rennes, Inserm, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France., Guegan H; Univ Rennes, CHU de Rennes, Inserm, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France; CHU Rennes, Laboratory of Parasitology and Medical Mycology, European Confederation of Medical Mycology (ECMM) Excellence Center, Centre National de Référence Aspergilloses Chroniques, F-35000 Rennes, France., Gangneux JP; Univ Rennes, CHU de Rennes, Inserm, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France; CHU Rennes, Laboratory of Parasitology and Medical Mycology, European Confederation of Medical Mycology (ECMM) Excellence Center, Centre National de Référence Aspergilloses Chroniques, F-35000 Rennes, France., Bellissant E; CHU Rennes, Laboratory of Biological Pharmacology, F-35000 Rennes, France; Univ Rennes, CHU de Rennes, Inserm, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France., Lemaitre F; CHU Rennes, Laboratory of Biological Pharmacology, F-35000 Rennes, France; Univ Rennes, CHU de Rennes, Inserm, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France.

Publikováno v: Infectious diseases now [Infect Dis Now] 2024 Sep; Vol. 54 (6), pp. 104955. Date of Electronic Publication: 2024 Jul 21.

Contribution of voriconazole N-oxide plasma concentration measurements to voriconazole therapeutic drug monitoring in patients with invasive fungal infection.

Autor: Boglione-Kerrien C; Department of Biological Pharmacology, CHU Rennes, Rennes, France., Morcet J; Inserm, CIC-P 1414 Clinical Investigation Centre, Rennes, France., Scailteux LM; Department of Clinical Pharmacology, Rennes University Hospital, Pharmacovigilance, Pharmacoepidemiology and Drug Information Centre, Rennes, France., Bénézit F; Department of Infectious Diseases, Rennes University Hospital, Rennes, France., Camus C; Department of Intensive Care Medicine, Rennes University Hospital, Rennes, France., Mear JB; Department of Clinical Haematology, Rennes University Hospital, Rennes, France., Gangneux JP; Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR_S 1085, Rennes, France., Bellissant E; Department of Biological Pharmacology, CHU Rennes, Rennes, France.; Inserm, CIC-P 1414 Clinical Investigation Centre, Rennes, France., Tron C; Department of Biological Pharmacology, CHU Rennes, Rennes, France.; Inserm, CIC-P 1414 Clinical Investigation Centre, Rennes, France., Verdier MC; Department of Biological Pharmacology, CHU Rennes, Rennes, France.; Inserm, CIC-P 1414 Clinical Investigation Centre, Rennes, France., Lemaitre F; Department of Biological Pharmacology, CHU Rennes, Rennes, France.; Inserm, CIC-P 1414 Clinical Investigation Centre, Rennes, France.

Publikováno v: Mycoses [Mycoses] 2023 May; Vol. 66 (5), pp. 396-404. Date of Electronic Publication: 2023 Feb 05.

Can we predict the influence of inflammation on voriconazole exposure? An overview.

Autor: Boglione-Kerrien C; Rennes University Hospital, Department of Biological Pharmacology, 2, rue Henri le Guilloux, F-35000 Rennes, France., Zerrouki S; Rennes University Hospital, Department of Biochemistry, Rennes, France., Le Bot A; Rennes University Hospital, Department of Infectious Diseases, Rennes, France., Camus C; Rennes University Hospital, Department of Intensive Care Medicine, Rennes, France., Marchand T; Rennes University Hospital, Department of Clinical Haematology, Rennes, France., Bellissant E; Rennes University Hospital, Department of Biological Pharmacology, 2, rue Henri le Guilloux, F-35000 Rennes, France.; INSERM, CIC-P 1414 Clinical Investigation Centre, Rennes, France.; Rennes University Hospital, INSERM, EHESP, IRSET (Institut de Recherche en Santé, Environnement et Travail) -UMR_S 1085, F-35000 Rennes, France., Tron C; Rennes University Hospital, Department of Biological Pharmacology, 2, rue Henri le Guilloux, F-35000 Rennes, France.; INSERM, CIC-P 1414 Clinical Investigation Centre, Rennes, France.; Rennes University Hospital, INSERM, EHESP, IRSET (Institut de Recherche en Santé, Environnement et Travail) -UMR_S 1085, F-35000 Rennes, France., Verdier MC; Rennes University Hospital, Department of Biological Pharmacology, 2, rue Henri le Guilloux, F-35000 Rennes, France.; INSERM, CIC-P 1414 Clinical Investigation Centre, Rennes, France.; Rennes University Hospital, INSERM, EHESP, IRSET (Institut de Recherche en Santé, Environnement et Travail) -UMR_S 1085, F-35000 Rennes, France., Gangneux JP; Rennes University Hospital, INSERM, EHESP, IRSET (Institut de Recherche en Santé, Environnement et Travail) -UMR_S 1085, F-35000 Rennes, France.; Rennes University Hospital, Department of Parasitology and Mycology, National Reference Centre for Mycoses and Antifungals (LA Asp-C) and European Excellence Centre in Medical Mycology (ECMM EC), Rennes, France., Lemaitre F; Rennes University Hospital, Department of Biological Pharmacology, 2, rue Henri le Guilloux, F-35000 Rennes, France.; INSERM, CIC-P 1414 Clinical Investigation Centre, Rennes, France.; Rennes University Hospital, INSERM, EHESP, IRSET (Institut de Recherche en Santé, Environnement et Travail) -UMR_S 1085, F-35000 Rennes, France.

Publikováno v: The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2023 Nov 06; Vol. 78 (11), pp. 2630-2636.

Switch from intravenous to subcutaneous infliximab in inflammatory bowel disease: Which consequences from a pharmacokinetic perspective?

Autor: Franck, B., Verdier, M.C., Bellissant, E., Bouguen, G., Lemaitre, F., Tron, C.

Publikováno v: Fundamental & Clinical Pharmacology
Fundamental & Clinical Pharmacology, 2022, 36, pp.43-43

International audience; Meeting Abstract CO-060

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2755::8c71dc1cea697f92a00f7cbd5196e738
https://hal.science/hal-03789365

Therapeutic drug monitoring of ruxolitinib in graft versus host disease in pediatric allogenic hematopoietic stem cell transplant recipients: A multicenter retrospective study

Autor: Franck, B., Lemaitre, F., Verdier, M. C., Felber, M., Rialland, F, Bellissant, E., Gandemer, V., Tron, C.

Publikováno v: Fundamental & Clinical Pharmacology
Fundamental & Clinical Pharmacology, 2022, 36, pp.147-147

International audience; Meeting Abstract PS-103

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2755::99acd92f7fefd0cf5dd8d51be99f8ed6
https://hal.science/hal-03789398